Riik: Iirimaa
keel: inglise
Allikas: HPRA (Health Products Regulatory Authority)
Carprofen
Zoetis Belgium S.A.
QM01AE91
Carprofen
20 mg/tablet
Tablet
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
carprofen
N.S.A.I.D.
Authorised
2015-03-06
Health Products Regulatory Authority 29 April 2020 CRN009NWW Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rimadyl Palatable Tablets 20 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg Carprofen. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Chewable tablets. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in the dog. Rimadyl Palatable Tablets can also be used in the management of post-operative pain. 4.3 CONTRAINDICATIONS Do not exceed the stated dose. The elimination time of NSAIDs, including carprofen, in the cat is longer than in the dog and the therapeutic index is narrower. In the absence of specific data the use of Rimadyl Palatable Tablets in the cat is contra-indicated. Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of blood dyscrasia or hypersensitivity to the product. Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use in dogs less than 6 weeks of age, or in aged dogs, may involve additional risk. If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. Concurrent administration of potential nephrotoxic drugs should be avoided. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy s Lugege kogu dokumenti